Michiaki Abe, Takuhiro Yamaguchi, Seizo Koshiba, Shin Takayama, Toshiki Nakai, Koichiro Nishioka, Satomi Yamasaki, Kazuhiko Kawaguchi, Masanori Umeyama, Atsuko Masaura, Kota Ishizawa, Ryutaro Arita, Takeshi Kanno, Tetsuya Akaishi, Mariko Miyazaki, Takaaki Abe, Tetsuhiro Tanaka, Tadashi Ishii
BACKGROUND: The beneficial effects of oral supplements with alkalinizing agents in patients with chronic kidney disease (CKD) have been limited to the severe stages. We investigated whether two types of supplements, sodium bicarbonate (SB) and potassium citrate/sodium citrate (PCSC), could maintain renal function in patients with mild-stage CKD. METHODS: This was a single-center, open-labeled, randomized cohort trial. Study participants with CKD stages G2, G3a, and G3b were enrolled between March 2013 and January 2019 and randomly assigned by stratification according to age, sex, estimated glomerular filtration rate (eGFR), and diabetes...
June 13, 2024: Clinical and Experimental Nephrology